This systematic review provides an assessment of the excited delirium syndrome (ExDS), including definition, epidemiology, pathophysiology, and management. Sixty-six relevant articles were included with significant heterogeneity of selected studies and poor overall quality. A quantitative meta-analysis could not be performed because there remains no clear definition for ExDS, however, this study does provide useful information regarding epidemiology, pathophysiology, and treatment of ExDS.
BACKGROUND
C ases of extreme agitation have been described since the 19th century, with Luther Bell's eponymous "Bell's mania" being described in October 1849. 1 The term excited delirium syndrome (ExDS) was not coined until the 1980s, after a flurry of deaths of individuals in custody or during arrests following extreme agitation. 2 These cases usually involved men in their 30s after cocaine, methamphetamine, or ecstasy abuse. [3] [4] [5] These cases were not limited to patients in custody, however, and fatal cases of ExDS appeared in the hospital without any trauma, physical restraint, or police intervention. 5 Given the significant morbidity and mortality rate of 8% to 10%, this syndrome remains of great importance to the emergency provider. 6, 7 Over 150 years since it was first described, we still do not have a standardized definition of ExDS and diagnostic criteria have not been universally recognized. 
ARTICLE SUMMARY

QUALITY ASSESSMENT
This was a thorough, evidence-based systematic review of the ExDS literature. The search strategy was broad and exhaustive, without language restriction, and included the gray literature (unpublished abstracts and conference proceedings using Google Scholar). It also included published U.S. and European official police reports or medical expert reports. GRADE was used to assess the quality of evidence and strength of recommendations of included studies.
Despite an extensive search, the overall quality of studies was poor, with only 66 relevant articles, most of which were retrospective case series. Only 10 studies were prospective, and the level of evidence was estimated as strong for only three articles related to pathophysiology or management of ExDS. Significant heterogeneity of selected studies, and the lack of a clear definition of ExDS prevented the performance of a quantitative metaanalysis. Finally, study sample sizes were often small and study designs were susceptible to many biases.
KEY RESULTS
From the initial search, 4,792 potentially relevant references were found; 66 of these were included. Each of these articles answered one or more of the four preplanned questions. All studies were in English except for a single Spanish forensic case series. The overall quality of included studies was low.
Definition/Diagnostic Criteria of ExDS
Three retrospective studies totaling 108 patients proposed a definition for ExDS. No universally accepted definition of ExDS was found, with the only prerequisite being "delirium associated with excited behavior or agitation."
Epidemiology of ExDS
Twenty-three articles related to epidemiology were included, from ExDS patients in the context of police interventions, prehospital services, the forensic setting, and in hospital. Overall, ExDS patients were mostly middle-aged men (14-71 years old; mean age = 33.3 years, median = 30.0 years, 83%-95% male).
Pathophysiology of ExDS
Thirty-eight articles were related to pathophysiology of ExDS or risk factors for mortality. Numerous hypotheses were described:
-Twelve articles hypothesized catecholamine surge, exogenous (drugs), endogenous (stress/physical exertion), or a combination of the two. -Nine articles proposed dopamine transporter pathway activation. -Six articles proposed individual variation/genetic susceptibility related to chronic stimulant-induced abnormalities or dopamine receptor variations. -Other proposed mechanisms included cocaine induced neurotoxicity from reactive oxygen species in the CNS and variations in alpha-synuclein protein or opioid receptors.
Drug abuse is the largest risk factor for ExDS and was associated with ExDS in 15 articles, cocaine being the most frequently associated drug.
Evidence-based Management and Treatment of ExDS
Twenty-seven articles on the management and treatment of ExDS were identified. Key points included:
-Restraint position: Do not restrain prone, move patients to a side lying or seated position as soon as possible. -Chemical sedation: Benzodiazepines (six articles), neuroleptics (two articles), benzodiazepines + neuroleptics (one article), and ketamine (14 articles).
AUTHORS' COMMENTS
The overall quality of studies was poor. A universally recognized definition is lacking, remaining mostly syndromic and based on subjective clinical criteria. The high mortality rate may be due to definition inconsistency and reporting bias. Our results suggest that ExDS is a real clinical entity with significant mortality and probably has specific mechanisms and risk factors. No comparative study has been performed to conclude whether one treatment approach is preferable to another in the case of ExDS.
TOP SOCIAL MEDIA COMMENTARY Comments from Twitter
There was a lot of discussion regarding the choice of chemical sedation agent for excited delirium, and opinions on the subject are divided (see Twitter Poll).
Twitter Poll
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Michael Perlmutter @DitchDoc14
If the patient presents an immediate threat to his/her own safety or that of staff, IM ketamine 4-5mg/kg should be the first treatment. Anything else unnecessarily risks everyone's safety. If that doesn't work, give more ketamine, intubate as needed. In true ExDS, there's probably a significant subset that require intubation as a component of care. It's not a failure of ketamine, it's excellent medical care for a life-threatening condition.
There was also a discussion between Minh Le Cong @ketaminh and Chip @the_TOTAL_EM about ketamine vs. droperidol vs. B-52 as sedation options. @ketaminh Honestly if you had droperidol you wouldn't need ketamine 60% of the time. @the_TOTAL_EM Don't have droperidol, but I do have ketamine and use it when I need immediate takedown like I do with excited delirium. Don't like B52 when patient is truly excited delirium. If I think they need a timeout and go to bed (not chemical takedown because they are an immediate threat), they get a B52: Benadryl (diphenhydramine) 50mg, haloperidol 5mg, lorazepam 2mg. Doses may vary.
Concern with B52 is it is slower in onset, has a more varied effect, and harder to re-dose. @ketaminh Haldol is too slow but it's safe. If you can give it and leave them safely for 20 min it's similar to droperidol effect after 20 min @the_TOTAL_EM If I can leave them safely for 20 minutes, they probably didn't need ketamine. They need a good nap. Haloperidol is fine for that like you said. I wish we had droperidol in the USA.
Meme by Chip @the_TOTAL_EM
Paper-in-a-pic from Kirsty Challen, @KirstyChallen
TAKE-TO-WORK POINTS
Excited delirium syndrome remains a poorly defined disease and is difficult to study because of its inconsistent definition. However, it is a dangerous, high-morbidity, and high-mortality condition that requires aggressive management in the ED.
